Equities research analysts at StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a note issued to investors on Monday. The brokerage set a “sell” rating on the stock.
Navidea Biopharmaceuticals Price Performance
Shares of Navidea Biopharmaceuticals stock opened at $0.05 on Monday. The stock has a market cap of $5.00 million, a price-to-earnings ratio of -0.17 and a beta of 1.57. The firm’s 50-day moving average is $0.07 and its 200 day moving average is $0.09. Navidea Biopharmaceuticals has a 1 year low of $0.02 and a 1 year high of $0.35.
Hedge Funds Weigh In On Navidea Biopharmaceuticals
Navidea Biopharmaceuticals Company Profile
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.
- Five stocks we like better than Navidea Biopharmaceuticals
- Large Cap Stock Definition and How to Invest
- MarketBeat Week in Review – 11/6 – 11/10
- ETF Screener: Uses and Step-by-Step Guide
- Data giants MongoDB and Snowflake just got upgraded
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.